Tirzepatide is a dual GIP and GLP-1 receptor agonist — a single molecule acting on two incretin pathways involved in glucose regulation, satiety signalling and energy balance. Supplied lyophilized and verified by third-party LC-MS.
| Purity | ≥99% (LC-MS verified) |
| Form | Lyophilized powder, preservative free |
| Storage | Cool and dry; refrigerate after reconstitution |
| Batch | COA available on request |
Tirzepatide is a dual GIP and GLP-1 receptor agonist — a single molecule acting on two incretin pathways involved in glucose regulation, satiety signalling and energy balance. Supplied lyophilized and verified by third-party LC-MS.
Tirzepatide is a dual agonist — a single 39-amino-acid synthetic peptide that binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. It was the first compound of its class to reach approval, and established that engaging two incretin pathways with one molecule produces a measurably different metabolic profile from GLP-1 agonism alone.
Supplied as lyophilized powder for laboratory research, preservative free, with third-party HPLC and LC-MS verification per lot.
Supplied for laboratory research use only. Not for human consumption.
Comparing this against the other one? Read the full retatrutide vs tirzepatide research comparison →
Receptor targets, development stage and the published evidence for both, side by side.
Tirzepatide's defining feature is simultaneous activity at GIP and GLP-1 receptors. GIP had been comparatively neglected as a target; the trial results renewed research interest in its contribution to insulin secretion and adipose tissue metabolism.
The SURPASS trials examined glycaemic endpoints and the SURMOUNT trials examined weight endpoints, both randomised and published in major journals. Several are open access and linked below.
A distinct strand of work uses imaging to separate fat mass from lean mass during weight reduction, addressing a question that simple weight endpoints cannot answer.
Head-to-head and real-world comparative work against semaglutide is an active area, examining whether dual agonism produces different outcomes from single-receptor agonism at comparable exposures.
Tirzepatide is an approved medicine in several jurisdictions when supplied as a finished pharmaceutical product. Research-grade material is not a finished pharmaceutical and is not for human consumption.
Concentration is set by the volume of diluent added. For a 10mg vial, 2mL of bacteriostatic water yields 5mg/mL. Calculate the working concentration your protocol requires rather than following a generic figure.
| State | Temperature | Practical shelf life |
|---|---|---|
| Lyophilized, sealed | −20 °C | 24+ months |
| Lyophilized, sealed | 2–8 °C | ~12 months |
| Lyophilized, sealed | Room temperature | Weeks — transit only |
| Reconstituted, bacteriostatic water | 2–8 °C | ~3–4 weeks |
| Reconstituted, sterile water | 2–8 °C | Same session |
Lyophilized peptide is stable enough to survive shipping at ambient temperature, which is why cold-chain courier service is not required for transit. Long-term storage is a different matter — material intended to be held for months belongs in a freezer.
Protect from light, and avoid repeated freeze-thaw cycles. Each cycle causes measurable degradation, so dividing a reconstituted stock into single-use aliquots before freezing is preferable to thawing and refreezing one vial repeatedly.
Every lot is tested by an independent laboratory using two orthogonal methods. HPLC (high-performance liquid chromatography) establishes purity as a percentage of total peptide content, separating the target compound from truncated sequences and synthesis by-products. LC-MS (liquid chromatography–mass spectrometry) confirms molecular identity by mass.
Both matter. Purity alone is insufficient — a 99% pure sample of the wrong compound is still the wrong compound. Together the two tests establish identity and quality, which is why Tirzepatide is released only after both pass.
The certificate of analysis references the lot number printed on your vial label. Request the COA for your lot at sales@pepsdepot.com.
Peer-reviewed studies indexed in PubMed. Each links to the abstract and, where a free copy exists, to the full text. We link primary sources rather than summarising them second-hand.
Compounds studied alongside this one, or acting through related pathways.
Join the Peps Depot mailing list for high-demand restock alerts, subscriber-only offers, release updates and priority access — plus The Friday Brief, our weekly peptide research newsletter covering what actually moved that week. New compounds, new trial data, regulatory shifts.